Dynavax doses first subject in Phase I/II shingles vaccine trial

Dynavax Technologies has dosed the first subject in a Phase I/II clinical trial of Z-1018, an investigational vaccine aimed at preventing shingles, also known as herpes zoster.

The active-controlled, randomised, dose escalation, multi-centre trial is anticipated to enrol around 440 healthy adults aged 50 to 69 years across multiple sites in Australia.